Showing results 21 to 38 of 38
  Strontium ranelate prevents spine osteoarthritis progression in patients with prevalent spinal osteoarthritisBruyère, Olivier  ; ; et alin Osteoporosis International (2007, March), 18(Suppl1), 16-17 Detailed reference viewed: 12 (1 ULg)Strontium ranelate decreases vertebral fracture risk whatever the level of pretreatment bone turnover markersCollette, Julien ; Reginster, Jean-Yves ; Bruyère, Olivier et alin Osteoporosis International (2007, March), 18(Suppl.1), 127-128 Detailed reference viewed: 9 (2 ULg)Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over five years in post menopausal osteoporotic womenReginster, Jean-Yves ; ; et alin Arthritis and Rheumatism (2006, November), 54(Suppl), Detailed reference viewed: 10 (0 ULg)Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia; ; Reginster, Jean-Yves et alin Osteoporosis International (2006, June), 17(Suppl.2), 85 Detailed reference viewed: 3 (1 ULg)Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic womenReginster, Jean-Yves ; ; et alin Osteoporosis International (2006, June), 17(Suppl.2), 14 Detailed reference viewed: 4 (1 ULg)Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors; Reginster, Jean-Yves ; et alin Osteoporosis International (2006, June), 17(Suppl.2), 92 Detailed reference viewed: 2 (0 ULg)Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia; ; Reginster, Jean-Yves et alin Osteoporosis International (2006, March), 17(Suppl.1), 50 Detailed reference viewed: 2 (0 ULg)Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic womenReginster, Jean-Yves ; ; et alin Osteoporosis International (2006, March), 17(Suppl.1), 11 Detailed reference viewed: 7 (1 ULg)Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors; Reginster, Jean-Yves ; et alin Osteoporosis International (2006, March), 17(Suppl.1), 50 Detailed reference viewed: 1 (0 ULg)Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelateBruyère, Olivier ; ; et alin Osteoporosis International (2006, March), 17(Suppl.1), 8 Detailed reference viewed: 9 (3 ULg) Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status; ; et al in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 359 Detailed reference viewed: 8 (6 ULg)Vertebral and non-vertebral anti-fracture efficacy of strontium ranelate in very elderly women with osteoporosis; ; et al in Osteoporosis International (2005, March), 16(Suppl.3), 6 Detailed reference viewed: 5 (0 ULg)The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis; ; et al in New England Journal of Medicine (2004), 350(5), 459-468 BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that ... [more ▼] BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density. METHODS: To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months. RESULTS: New vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group, with a risk reduction of 49 percent in the first year of treatment and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month 36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P<0.001 for both comparisons). There were no significant differences between the groups in the incidence of serious adverse events. CONCLUSIONS: Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures. [less ▲] Detailed reference viewed: 16 (3 ULg)Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic womenBruyère, Olivier ; Collette, Julien ; et alin Maturitas (2003), 44(4), 259-265 Objective: To analyse the interest of baseline levels and short-term (3-months) changes in serum osteocalcin (BGP), serum bone-specific alkaline phosphatase (BALP) and urinary C-telopeptide of type I ... [more ▼] Objective: To analyse the interest of baseline levels and short-term (3-months) changes in serum osteocalcin (BGP), serum bone-specific alkaline phosphatase (BALP) and urinary C-telopeptide of type I collagen/creatinine ratio (U-TX) to predict 3-years changes in bone mineral density (BMD) and spinal deformity index (SDI) in postmenopausal osteoporotic women. Methods: Data were derived from a cohort of 603 osteoporotic women corresponding to the placebo arm of a 3-years prospective, double-blind study. Results: Baseline values of BALP, BGP and U-CTX were negatively and significantly correlated with baseline spinal BMD. Significant correlations were also observed between the changes in BMD observed after 36 months at the spine and baseline BALP (r = 0.20, P = 0.0001), BGP (r = 0.09, P = 0.05) and U-CTX (r = -0.11, P = 0.02). At 3 years, 71 women (15.9%) showed an increase in their SDI, corresponding to the occurrence of at least one new vertebral deformity. Baseline values of the four bone turnover markers (BTM) were not significantly related to the occurrence of new vertebral deformities. However, when considering the changes in the BTM observed after 3-months of follow-up, BGP (P = 0.003) and U-CTX (P = 0.047) were identified as significant predictors of an increase of SDI. The associated odds ratios (95% confidence interval (CI)) were 10.922 (2.218-53.78) for unit changes of log BGP and 1.369 (1.003-1.867) for unit changes of log U-CTX. The relative risk (RR) (IC 95%) of having a new vertebral fracture over 36 months was 0.31 (0.15-0.65) when being in the lowest quartile of 3-months changes in BGP as compared with the highest. Conclusion: We conclude that two sequential measurements of BGP and U-CTX performed at 3-months intervals could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertebral deformities. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved. [less ▲] Detailed reference viewed: 17 (5 ULg)Strontium ranelate treatment prevents health related quality of life impairement in results from the SOTI study; ; et al in Osteoporosis International (2002, November), 13(Suppl.3), 11 Detailed reference viewed: 1 (0 ULg)Strontium ranelate: new efficient anti-osteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women; ; et al in Osteoporosis International (2002, November), 13(Suppl.3), 34 Detailed reference viewed: 11 (0 ULg)Early (3-month) changes in serum osteocalcin and urinary C-telopeptide of type I collagen could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertebral deformitiesBruyère, Olivier ; COLLETTE, Julien ; et alin Arthritis and Rheumatism (2001), 44(Suppl.1), 257 Detailed reference viewed: 7 (0 ULg)Early (3-month) changes in serum osteocalcin and urinary C-telopeptide of type I collagen could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertevral deformitiesBruyère, Olivier ; COLLETTE, Julien ; et alin Clinical Rheumatology (2001), 5(Suppl.1), 426 Detailed reference viewed: 4 (2 ULg)
|
||
